Targeting eosinophilic asthma by rebalancing immune responses and Th2 cytokines. Clinically proven to improve lung function and address the underlying cause of inflammation.
The clinical development of AD17002 has expanded into eosinophilic asthma, demonstrating the platform's versatility beyond infectious disease. AD17002 has shown a favorable safety profile in patients with asthma, meeting a critical requirement for this population. In a completed Phase IIa study, treatment led to meaningful modulation of eosinophil counts, improved lung function, and favorable regulation of Th2-biased cytokines that drive eosinophilic inflammation (NCT05985694). These results indicate an ability to rebalance underlying immune dysregulation rather than merely to control symptoms. A Phase II clinical trial is currently underway to further evaluate efficacy and durability, positioning AD17002 as a differentiated, immune-modulating therapy with strong commercial potential in eosinophilic asthma (NCT07250594).
Allergic Rhinitis Immunotherapy — Phase IIa (NCT04088721) AD17002 is effective in attenuating allergic symptoms, including turbinate redness and swelling.
Eosinophilic Asthma Immunotherapy — Phase IIa (NCT05985694), Phase II (NCT07250594, ongoing) AD17002 treatment led to meaningful modulation of eosinophil counts, improved lung function, and favorable regulation of Th2-biased cytokines.
back to overview
